Related Experiment Video
Updated: Jun 1, 2026
In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection
Published on: November 27, 2014
Safety and immunogenicity of a chimeric vaccine for West Nile virus in aged subjects
1Department of Microbiology and Immunology, Sealy Center for Vaccine Development, Center for Biodefense and Emerging Infectious Disease, Institute for Human Infections and Immunity, Galveston, TX, USA. d.beasley@utmb.edu
Abstract:
A recent Phase II clinical trial has demonstrated comparable safety and immunogenicity of ChimeriVax-WN02, a chimeric West Nile virus (WNV) vaccine candidate based on yellow fever 17D, in small cohorts of healthy adults aged 18-40, 41-64 and 65-80 years. Adults ≥65 years of age are an important target population for candidate WNV vaccines as they have a high risk for severe WNV neuroinvasive disease. The apparent safety and immunogenicity of ChimeriVax-WN02 in this population indicates that further development and clinical testing are justified.
